MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adverum Biotechnologies, Inc. - Common Stock (NQ:ADVM)

4.300 +0.070 (+1.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Adverum Biotechnologies, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections
Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones. 
Via Benzinga
Eli Lilly To Acquire Adverum Biotechnologies
Via Stocktwits
In today's session, these stocks are experiencing unusual volume.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Top movers in Wednesday's pre-market session
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q2 2024
ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Around $88M Bet On NextDecade? Check Out These 3 Stocks Insiders Are Buying
 
Via Benzinga
More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying
 
Via Benzinga
Adverum Releases Interim Data From Gene Therapy Study For Blindness Disorder, Prepares For Pivotal Study
Adverum Biotechnologies presented 26-week interim data from the LUNA Phase 2 trial for Ixo-vec in wet AMD. The analysis showed significant reductions in anti-VEGF injections and positive visual... 
Via Benzinga
Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
 
Via Benzinga
ADVM Stock Earnings: Adverum Biotechnologies Misses EPS for Q1 2024
ADVM stock results show that Adverum Biotechnologies missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and... 
Via Benzinga
ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023
ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop
There are plenty of penny stocks ready to pop but we have to remember that penny stocks are extremely risky, too. 
Via InvestorPlace
Stocks on the Launchpad: The Next 3 Market Sensations
Navigate the bullish trend in the market by wagering on these three enticing market sensations likely to become multi-bagger investments 
Via InvestorPlace
Unleash Massive Returns With These 3 Top Penny Stocks
Our economy is doing well, and these top penny stocks are in position to benefit from this. Invest now and see strong returns. 
Via InvestorPlace
Topics Economy
Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Adverum Biotechnologies Stock Is Trading Higher
Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock's 30-day volume-weighted average price, and the financing is expected to close on... 
Via Benzinga
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during... 
Via Benzinga
Over $14M Bet On Diversified Healthcare Trust? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by over 40 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story